State Street
LIMN

State Street’s Liminatus Pharma LIMN Stock Holding History

State Street’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1K Hold
19,000
– – ﹤0.01% 4175
2026
Q1 		$3.27K Hold
19,000
– – ﹤0.01% 4265
2025
Q4 		$11.6K Hold
19,000
– – ﹤0.01% 4265
2025
Q3 		$31.7K Hold
19,000
– – ﹤0.01% 4209
2025
Q2 		$212K Buy
+19,000
New +$213K ﹤0.01% 3815

Other funds holding LIMN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street's LIMN Position: Q2 2026 in Review

State Street held its Liminatus Pharma (LIMN) position steady in Q2 2026 at 19,000 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4175.

State Street first reported a position in LIMN in Q2 2025 and has held it in 5 quarters since. The position peaked at $212K in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • State Street held 19,000 shares of Liminatus Pharma worth $2.1K as of Q2 2026.
  • State Street left its Liminatus Pharma share count unchanged in Q2 2026.
  • Liminatus Pharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4175 holding.
  • State Street first reported a position in Liminatus Pharma in Q2 2025 and has held it in 5 quarters since.
  • State Street's Liminatus Pharma position peaked at $212K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.